AzTrials
AzTrials

HIV InfectionsNCT07226323

Testing the WeCare Intervention to Address Mental Health and Medication Adherence Challenges Among MSM in South Africa

A study testing WeCare in people with HIV Infections and Mental Health, run by Emory University at 1 site in South Africa.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if the WeCare intervention-an adapted Friendship Bench program that integrates problem-solving therapy, minority-stress-informed content, and explicit PrEP/ART adherence skills-improves mental health and HIV medication adherence among men who have sex with men (MSM). Read more about this study

Who is it for?
Ages 18 years and older, men onlyHealthy volunteers can take part
Conditions the study is for
HIV Infections, Mental Health
What is being tested?
WeCare
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteSouth Africa
Study dates
1 Dec 2025to 31 Jul 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Male
  • reports sexual intercourse with a man in the past 6 months
  • reside in the Johannesburg metropolitan area with no plans to relocate during the next 6 months
  • ability to communicate in English
  • current prescription for any ART regimen (HIV-positive participants) or daily oral PrEP (HIV-negative participants) at the POP INN clinic.
  • HIV positive participant only: unsuppressed HIV viral load (HIV-1 RNA viral load ≥200 copies/mL) in the sample collected in the past six months
Show all 9Show fewer
  • HIV negative participants only: Self-reported challenges adhering to daily oral PrEP (i.e miss 3 or more tablets per week)
  • Moderate symptoms of depression during past 2 weeks (score on the PHQ-9 ≥10 and <20)
  • Ability to understand and provide informed consent.

Who cannot join

  • Presently engaged in mental health therapy.
  • Participated in qualitative phase of WeCare study (AUR2-18-419) or open-pilot (present study).
  • Refuses audio recording of the in-person or online individual counselling session

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Don Operario, PhD contact

404-727-0503

don.operario@emory.edu

Danielle Giovenco, PhD contact

404-727-3956

danielle.giovenco@emory.edu

South Africa1 site, 1 recruiting
  • Aurum Institute

    Johannesburg

    Eduard Sanders, : +254-723-593-762, ESanders@auruminstitute.org

    Recruiting

Other trials in South Africa

About this study

The goal of this clinical trial is to learn if the WeCare intervention-an adapted Friendship Bench program that integrates problem-solving therapy, minority-stress-informed content, and explicit PrEP/ART adherence skills-improves mental health and HIV medication adherence among men who have sex with men (MSM). It will also assess the safety, acceptability, and feasibility of delivering WeCare through trained lay coaches in community clinics.

Main questions the trial aims to answer:

  • Does WeCare reduce symptoms of depression and anxiety among MSM?
  • Does WeCare improve PrEP and ART adherence and increase rates of viral suppression among participants on ART?
  • Is WeCare acceptable, feasible, and safe when delivered by lay coaches in POP INN clinics compared with usual care?
Read the detailed description

Men who have sex with men (MSM) in sub-Saharan Africa face very high HIV incidence and prevalence, with South Africa carrying the largest national burden and an estimated ~30% HIV prevalence among MSM. National policies in South Africa endorse universal test-and-treat and prioritize MSM for Pre-Exposure Prophylaxis (PrEP) and Anti-Retroviral Therapy (ART), but care cascade indicators and adherence outcomes for MSM lag behind national averages, indicating a need for differentiated, targeted service approaches.

Common mental health problems are prevalent among MSM and are strongly associated with poorer PrEP and ART adherence. Randomized and quasi-experimental trials in the region show that lay-delivered or nurse-delivered mental health interventions can reduce depression and improve ART adherence and viral suppression, while observational studies link poor mental health to lower PrEP adherence and limited trial evidence suggests integrated adherence interventions may improve biomarker outcomes.

The Friendship Bench (FB) model-an evidence-based, lay health worker-delivered problem-solving therapy program developed in Zimbabwe and adapted across low-resource settings-produces substantial reductions in depressive symptoms and can be delivered in person or digitally. FB's original form had limited effects on ART adherence, prompting calls to explicitly integrate adherence counseling; systematic adaptation is required to make FB effective for MSM by incorporating minority stress theory, addressing anti-MSM stigma and disclosure challenges, and adding explicit adherence skills training.

Aurum's POP INN clinics provide MSM-friendly services and peer support and have piloted FB-style coaching, revealing high rates of medication adherence challenges and moderate-to-severe depression among MSM. Pilot quantitative and qualitative data identify predictors of non-suppression and adherence problems-such as clinic location, transactional sex, missed doses, anxiety, and shorter ART duration-and show a clear preference among MSM for HIV status-neutral programming. Building on these findings, the proposed WeCare intervention aims to adapt Facebook into a status-neutral, minority-stress-informed package that integrates problem-solving therapy with explicit PrEP/ART adherence support, delivered by trained lay coaches, to improve mental health, medication adherence, viral suppression, stigma reduction, and community cohesion.

Being tested
WeCare, Standard of Care
Keywords
Men having sex with Men, Medication adherence, PrEP Adherence, ART Adherence
Medical subject headings
HIV Infections, Psychological Well-Being, Medication Adherence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • WeCareBehavioural

    The intervention is an adapted Friendship Bench (FB) for MSM in South Africa that integrates counseling on HIV medication adherence and the mental health-adherence relationship. The intervention includes up to 4 individual sessions and up to 4 group sessions; individual sessions may be delivered in person or online (Inuka-style), while all group sessions are in person.

  • Standard of CareBehavioural

    The control group will receive enhanced standard care at POP INN Wellness Clinic: psychoeducation for all PrEP/ART enrollees, free medication, access to ongoing support groups, and referrals provided by the clinic.

Study groups in NCT07226323
Study groupRoleWhat they receive
Friendship Bench (FB) armExperimentalNot described
Receives: Behavioral: WeCare
Control ArmOtherNot described
Receives: Behavioral: Standard of Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment : Modified version of the Session Evaluation Form (SEF) score

    13-item SEF measuring perceived feasibility, acceptability, and intervention utility.

    Composite scores are calculated with higher scores indicating more perceived feasibility and acceptability.

    Measured: Baseline, Month 3, Month 6

  2. Change in Client Satisfaction Survey (CSQ-8) score

    8-item CSQ assessing satisfaction with recruitment, retention, and intervention procedures, engagement data from the trial (e.g., completion of sessions).

    Composite scores are calculated with higher scores indicating more satisfaction.

    Measured: Baseline, Month 3, Month 6

  3. Mental health measures: Change in The Patient Health Questionnaire (PHQ-9) scores

    The Patient Health Questionnaire (PHQ-9) measures the frequency of depression symptoms within the past two weeks. The PHQ-9 comprises five categories, where a cut-off point of 0-4 indicates no depressive symptoms, 5-9 mild depressive symptoms, 10-14 moderate depressive symptoms, 15-19 moderately-severe depressive symptoms, and 20-27 severe depressive symptoms

    Measured: Baseline, Month 3, Month 6

  4. Change in Psychological stress: WHO Self-Reporting Questionnaire-20 (SRQ-20) score

    The WHO Self-Reporting Questionnaire-20 (SRQ-20) includes items to reflect symptoms of depression, anxiety and psychosomatic complaints, which are all together grouped under the heading of common mental disorder (CMD) and have been found to detect probable mental health disorder with satisfactory accuracy

    Measured: Baseline, Month 3, Month 6

  5. Change in ART adherence

    ART adherence will be defined as a suppressed HIV viral load (HIV-1 RNA viral load <200 copies/mL) in a blood sample

    Measured: Baseline, Month 3, Month 6

  6. Change in PrEP adherence

    PrEP adherence will be defined as an intracellular Tenofovir Diphosphate (TFV-DP) concentration ≥700 fmol/punch in a dried blood spot (DBS) sample. This concentration was found consistent with an average of ≥4 doses/week in the prior month in a directly observed study among men and women in the United States

    Measured: Baseline, Month 3, Month 6

Secondary outcomes (2)
  1. Self reported medication adherence

    Adherence outcomes will be based on self-report data, where participants will be asked, "How many days did you not take your PrEP in the past 30 days (0-30 days)

    Measured: Baseline, Month 3, Month 6

  2. Status neutral composite adherence

    Based on Tenofovir Diphosphate (TFV-DP) concentration ≥700 fmol/punch OR HIV-1 RNA viral load <200 copies/ml

    Measured: Baseline, Month 3, Month 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Nov 2025
  2. Study start1 Dec 2025
  3. Primary completion31 Jul 2027 (estimated)
  4. Study completion31 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07226323
Sponsor's protocol ID
STUDY00009339
Other IDs
5R34MH135806-02, 2025P010078
Status last verified
Mar 2026
First submitted
7 Nov 2025
Last updated
29 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared with researchers who submit a methodologically sound proposal. Data will be collected by Aurum; Aurum will share de-identified data with Emory (including data dictionaries).

Questions about this trial

What is this clinical trial studying?

A study testing WeCare in people with HIV Infections and Mental Health, run by Emory University at 1 site in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Don Operario, PhD (404-727-0503, don.operario@emory.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment : Modified version of the Session Evaluation Form (SEF) score (time frame: Baseline, Month 3, Month 6). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in